Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 102
- Registration Number
- NCT01032837
A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT01033734
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 452
- Registration Number
- NCT01026142
- Locations
- 🇧🇪
UZ Brussel, Brussel, Belgium
🇭🇰Queen Mary Hospital; Surgery, Hong Kong, Hong Kong
🇷🇺Semashko Central Clinical Hospital; Dept of Chemotherapy, Moscow, Russian Federation
A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 206
- Registration Number
- NCT01022346
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2118
- Registration Number
- NCT01018173
A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT01017302
A Study With RO4917523 in Patients With Fragile X Syndrome
- Conditions
- Fragile X Syndrome
- Interventions
- Drug: Placebo (for RO4917523 ascending doses)Drug: Placebo (for RO4917523 fixed dose)
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01015430
A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT01014442
- Locations
- 🇩🇪
Department of Cardiothoracic, Transplantation and Vascular Surgery at Hannover Medical School, Hannover, Germany
An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys
- Conditions
- Hepatitis B, Chronic
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1842
- Registration Number
- NCT01011738
- Locations
- 🇦🇹
Tiroler Landeskrankenanstalten Ges.M.B.H.; Klinische Abt. Für Gaströnterologie & Hepatologie, Innsbruck, Austria
🇦🇹Medizinische Universität Wien; Univ.Klinik für Innere Medizin III - Gastroenterologie & Hepatologie, Wien, Austria
🇧🇩The Liver Centre, Dhaka, Bangladesh
A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT01010503